Pacemaker

Basic Function and Operating Modes

A pacemaker operates on the principle of demand pacing, where it continuously monitors the heart's intrinsic electrical rhythm. When the device fails to detect native heart electrical activity within a predetermined interval, typically around one second, it delivers a short, low-voltage pulse to stimulate the appropriate heart chamber. If intrinsic activity is sensed, the device inhibits its output, holding off stimulation. This cycle repeats on a beat-by-beat basis to ensure a consistent heart rate. The minimum voltage required to consistently stimulate the heart muscle is known as the pacing threshold, and devices are programmed to deliver pulses at a voltage margin above this level, usually 50 to 100 percent higher, to ensure reliable capture.

Pacemakers are classified by standardized codes that describe which chambers are paced and sensed. The basic ventricular demand mode is VVI, or VVIR when it includes rate responsiveness for exercise. The equivalent atrial mode is AAI or AAIR, suitable when atrioventricular conduction is intact but the sinoatrial node is unreliable. For atrioventricular block, VDD mode senses atrial activity and triggers a ventricular beat after a programmable delay. The most comprehensive mode is DDDR, which can pace and sense in both the atrium and ventricle while providing rate response. The device's ability to sense intrinsic signals is governed by its sensitivity setting, which must be carefully programmed to avoid oversensing of non-cardiac signals or undersensing of genuine heartbeats.

The electrical circuit for pacing can be configured as bipolar or unipolar. In a bipolar configuration, both the cathode and anode are contained within a single lead placed in the heart. In a unipolar setup, the lead provides one connection, and the second connection is completed through the body tissues to the pacemaker generator itself. The impedance of the pacing circuit is an important factor, as lower impedance requires more current to achieve the threshold voltage, which in turn reduces battery longevity. Impedance is affected by the integrity of the pacing lead and the interface between the electrode and the heart tissue.

Types of Pacemakers and Pacing Methods

Permanent pacemakers are categorized by the number of heart chambers they engage. A single-chamber pacemaker uses one lead placed in either the right atrium or the right ventricle. A dual-chamber pacemaker uses two leads, one in the right atrium and one in the right ventricle, which helps coordinate the timing between atrial and ventricular contractions to mimic natural heart function more closely. A biventricular pacemaker, used for cardiac resynchronization therapy, employs three leads to pace both ventricles and often the right atrium. Rate-responsive pacemakers incorporate sensors, such as accelerometers, to detect physical activity and automatically increase the pacing rate to meet metabolic demands.

Several temporary and emergency pacing methods exist outside of permanent implantation. Percussive pacing, or transthoracic mechanical pacing, is an old, life-saving technique involving a sharp blow to the sternum to induce a ventricular beat, and it must raise ventricular pressure to 10-15 mmHg to be effective. Transcutaneous pacing is a common emergency procedure where external pads on the chest deliver electrical impulses to stabilize a patient with significant bradycardia until more definitive therapy can be applied. Temporary transvenous pacing involves threading a pacing wire through a vein into the right heart, connecting it to an external generator as a bridge to permanent pacemaker placement. Epicardial pacing leads can be placed directly on the heart's outer surface during open-heart surgery if the procedure causes heart block, and these leads can be either passively sewn in place or actively fixed with a screw mechanism.

Leadless pacemakers are devices that are as small as a capsule. They are small enough to allow the generator to be placed within the heart. This design avoids the need for pacing leads. Leadless pacemakers can be implanted into the heart using a steerable catheter fed into the femoral vein via an incision in the groin. As pacemaker leads can fail over time, a pacing system that avoids these components offers theoretical advantages.

The Implantation Procedure and Long-Term Management

Pacemaker implantation is a surgical procedure typically performed under local anaesthetic, often with sedation, though general anaesthetic can be used. An antibiotic is administered to reduce infection risk, and the skin is prepared by clipping hair and cleaning with a disinfectant like chlorhexidine. The most common site is the upper chest, where an incision is made below the collarbone and a pocket is created under the skin, usually above the pectoralis major muscle, to house the generator. The pacing leads are then inserted into a large vein, such as the subclavian vein, and guided under fluoroscopic X-ray imaging to their final positions within the heart's chambers, which may be the right ventricle, right atrium, or coronary sinus. The procedure is generally completed within 30 to 90 minutes, and following implantation, patients must keep the surgical wound clean and dry until healed while avoiding certain arm and shoulder movements to prevent lead dislodgement.

The pacemaker generator contains a lithium-iodide battery with a typical lifespan of 5 to 10 years, after which the entire generator requires replacement. The replacement procedure involves making an incision over the existing device, disconnecting the leads from the old generator, and reconnecting them to a new one before closing the incision. This operation is usually simpler than the initial implant. After implantation, the device is checked periodically to monitor battery status, lead integrity, and pacing parameters, with checks conducted remotely or in a clinic as often as deemed necessary by the healthcare team.

Conventional placement of ventricular leads in or around the tip or apex of the right ventricle is called RV apical pacing. It has been associated with increased risk of atrial fibrillation, heart failure, and weakening of the heart muscle. It is also potentially associated with shorter life expectancy. The DAVID trials have shown that unnecessary pacing of the right ventricle can exacerbate heart failure and increases the incidence of atrial fibrillation. Newer dual-chamber devices can keep the amount of unnecessary right ventricular pacing to a minimum.

Cardiac Resynchronization Therapy for Heart Failure

Cardiac resynchronization therapy is a specialized pacing treatment for patients with heart failure who have ventricular dyssynchrony, meaning the left and right ventricles do not contract simultaneously. This condition is present in approximately 25 to 50 percent of heart failure patients. CRT uses a biventricular pacemaker to pace both the septal and lateral walls of the left ventricle, resynchronizing the contractions to improve the heart's pumping efficiency and coordination. The therapy is indicated for patients with heart failure symptoms, a left ventricular ejection fraction of 35 percent or less, and a QRS duration on an electrocardiogram of 120 milliseconds or greater, and it has been shown to reduce mortality and improve quality of life.

A CRT device requires at least two leads. One lead passes through the vena cava and right atrium into the right ventricle to stimulate the septum. A second lead is passed through the vena cava and right atrium, then inserted through the coronary sinus to pace the epicardial wall of the left ventricle. For patients in normal sinus rhythm, a third lead is often placed in the right atrium to maintain synchrony with atrial contraction. The timing between atrial and ventricular contractions, as well as between the two sides of the left ventricle, can be finely adjusted to optimize cardiac output. When CRT is combined with an implantable cardioverter-defibrillator, the device is called a CRT-D, which provides the benefits of resynchronization while also offering protection against life-threatening ventricular arrhythmias through defibrillation.

Advancements in Conduction System Pacing and Dynamic Function

Conduction system pacing has emerged as a significant advancement aimed at creating a more natural ventricular activation pattern. This approach includes His bundle pacing and left bundle branch area pacing, where a special lead is used to stimulate the heart's native His-Purkinje fibre network directly. By activating the natural conduction pathways, HBP can produce a perfectly synchronized ventricular activation, avoiding the long-term negative effects associated with traditional right ventricular pacing, and in some cases it can even correct pre-existing bundle branch block patterns. In February 2026, King George’s Medical University in Lucknow introduced an Advanced Conduction System Pacing technique, implanting three pacemakers using this method to improve inter-chamber coordination.

Another major functional advancement has been the development of rate-responsive and dynamic pacemakers. Early pacemakers provided a fixed heart rate, but modern devices attempt to mimic nature by using various physiological inputs to adjust pacing rate dynamically. The first dynamic pacemaker was invented by Anthony Rickards of the National Heart Hospital in London in 1982. Sensors can monitor parameters like the QT interval, dissolved oxygen or carbon dioxide levels in the arterial-venous system, physical activity via accelerometer, body temperature, and adrenaline levels. This allows the pacemaker to compensate for both actual and anticipated metabolic or respiratory loading, moving beyond simple intermittent control to a more physiological form of support that could also be applied to future artificial hearts.

Dynamic pacemaking technology could also be applied to future artificial hearts. Advances in transitional tissue welding would support this and other artificial organ replacement efforts. Stem cells may be of interest in transitional tissue welding. Many advancements have been made possible by the transition to microprocessor controlled pacemakers. Dual-chamber pacemakers control both the atria and ventricles. Rate responsive pacing allows the device to sense physical activity and adjust the base pacing rate.

Market Context, Drivers, and Clinical Research

The global cardiac pacemaker market is a significant and steadily growing segment of the medical device industry. It was valued at an estimated US$5.3 billion in 2026 and is projected to reach US$7.3 billion by 2033, reflecting a compound annual growth rate of 4.6 percent during that forecast period. A primary driver is the rising global prevalence of bradycardia and other arrhythmias, coupled with demographic trends like an aging population, as the World Health Organization projects continued growth in the population aged 60 and above. The growing adoption of conduction system pacing, which uses the heart's natural conduction pathways, is encouraging electrophysiologists to shift patients away from conventional right ventricular pacing toward more physiological approaches.

Market growth is further reinforced by technological adoption that expands therapy candidacy. The growing use of leadless pacemakers lowers procedural complications and recovery times, encouraging electrophysiologists to consider pacing for a broader patient group. Expanding leadless pacemaker adoption reinforces demand by eliminating the surgical pocket and transvenous leads associated with traditional implants, which reduces infection risk and complication rates. A market restraint is the limited battery life of devices, which necessitates replacement surgeries that add healthcare costs and expose patients to additional risks like infection and bleeding, and this need can discourage some patients and providers from adopting devices with higher replacement costs.

Ongoing clinical research continues to refine patient selection and understand outcomes. The LANDMARK multicentre trial, for example, includes sub-studies reported in 2026 examining the incidence and predictors of pacemaker dependency and low ventricular pacing rates one year after procedures like transcatheter aortic valve implantation. Other studies focus on the recovery of the heart's natural conduction after permanent pacemaker implantation. The expansion of cardiac care infrastructure in regions like Asia Pacific and the Middle East, along with a growing focus on remote patient monitoring capabilities in new devices and companies investing in MRI-conditional labeling, is expected to support long-term market demand and continued innovation in pacing technology.

Questions about Pacemaker

What is the main purpose of a pacemaker?

The primary purpose of a pacemaker is to maintain an adequate and regular heart rate. It does this when the heart's natural pacemaker is too slow, irregular, or when there is a blockage in the heart's electrical conduction system. The device generates electrical pulses that cause the heart chambers to contract and pump blood. By regulating the heart's rhythm, it alleviates symptoms like fatigue, dizziness, and fainting associated with bradycardia.

How long does a pacemaker battery last?

The battery in a pacemaker generator typically lasts between 5 and 10 years, though the exact lifespan depends on the device type and how much it is used. When the battery is nearing depletion, the device signals during a routine checkup. A replacement procedure is then scheduled, which involves surgically removing the old generator and connecting the existing leads to a new one. This procedure is generally simpler and quicker than the initial implantation.

What is a leadless pacemaker?

A leadless pacemaker is a miniaturized device, about the size of a large capsule, that is implanted entirely within the heart. It eliminates the need for the insulated wires, or leads, and the surgical pocket under the skin required by traditional pacemakers. The device is implanted using a catheter fed through a vein in the groin. This approach reduces the risk of lead-related complications and infections, and it shortens recovery time for patients.

What is cardiac resynchronization therapy?

Cardiac resynchronization therapy is a specialized form of pacing used to treat certain patients with heart failure. It employs a biventricular pacemaker to coordinate, or resynchronize, the contractions of the heart's left and right ventricles when they are not beating simultaneously. This coordinated pumping improves the heart's efficiency, which can reduce symptoms, improve quality of life, and lower mortality. The therapy is often combined with a defibrillator in a device known as a CRT-D.

What are the risks of pacemaker surgery?

As with any surgery, pacemaker implantation carries risks, though it is generally considered safe. Potential complications include infection at the implant site, bleeding or bruising, damage to blood vessels or nerves, and a collapsed lung. There is also a small risk that the pacing leads could move out of position, a problem called lead dislodgement. Patients are advised to avoid certain arm movements shortly after surgery to minimize this risk. The procedure is performed under sterile conditions, and antibiotics are given to reduce infection risk.

What is conduction system pacing?

Conduction system pacing is an advanced technique that aims to pace the heart using its natural electrical pathways, specifically the His-Purkinje network. This includes methods like His bundle pacing and left bundle branch area pacing. By stimulating these natural conduction tissues, the pacemaker creates a more synchronized and natural ventricular activation pattern. This approach may avoid some of the negative long-term effects associated with traditional right ventricular pacing, such as weakening of the heart muscle, and can sometimes correct existing bundle branch blocks.

Sources: Wikipedia and current public reporting, checked by the Your Space Hamilton desk. Last updated 2026-10-20.